Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of ALD518 for prevention/treatment of oral mucositis in head and neck cancer patients receiving chemoradiotherapy
2011-002669-40Phase 2Terminated
- Sponsor
- Alder Biopharmaceuticals
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in stomatitis (2 arms), sponsored by Alder Biopharmaceuticals. Primary endpoint: Primary Safety Endpoint. Started Aug 2011; status: terminated.
02
Drugs
clazakizumab
03
Conditions
stomatitis
Beyond the preview
Go deeper on 2011-002669-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002669-40.